Cargando…

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)

Oncolytic immunotherapeutics (OIs) are viruses designed to preferentially replicate in and lyse cancer cells, thereby triggering antitumor immunity. Numerous oncolytic platforms are currently in clinical development. Here we review preclinical and clinical experience with Pexa-Vec (pexastimogene dev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Breitbach, Caroline J, Bell, John C, Hwang, Tae-Ho, Kirn, David H, Burke, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918374/ https://www.ncbi.nlm.nih.gov/pubmed/27512667 http://dx.doi.org/10.2147/OV.S59640

Ejemplares similares

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
por: Parato, Kelley A, et al.
Publicado: (2012)

Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma
por: Lun, XueQing, et al.
Publicado: (2010)

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
por: Cousin, Sophie, et al.
Publicado: (2022)

Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma
por: Kung, Che-Hsuan, et al.
Publicado: (2015)

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
por: Toulmonde, Maud, et al.
Publicado: (2022)

Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
por: Monge, Cecilia, et al.
Publicado: (2023)

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
por: Moehler, Markus, et al.
Publicado: (2014)

Oncolytic Viruses: Therapeutics With an Identity Crisis
por: Breitbach, Caroline J., et al.
Publicado: (2016)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
por: Rehman, Hasan, et al.
Publicado: (2016)

Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
por: Meyers, Daniel E., et al.
Publicado: (2017)

Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
por: Meyers, Daniel E., et al.
Publicado: (2017)

The ABCB7-Like Transporter PexA in Rhodobacter capsulatus Is Involved in the Translocation of Reactive Sulfur Species
por: Riedel, Simona, et al.
Publicado: (2019)

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma
por: Ahamadi, Malidi, et al.
Publicado: (2023)

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors
por: Gibson, Heather, et al.
Publicado: (2015)

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
por: Ricca, Jacob M., et al.
Publicado: (2018)

Complete mitochondrial genome sequence of the phytopathogenic fungi Sclerotinia sclerotiorum JX-21
por: Xu, Zhilan, et al.
Publicado: (2016)

Portrait of a Leader in Immunotherapeutics: Oncolytic viruses for treatment of cancer
por: Hemminki, Akseli
Publicado: (2012)

Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review
por: Lalu, Manoj, et al.
Publicado: (2019)

Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma
por: Ohnesorge, Paul V., et al.
Publicado: (2022)

Surfactant Protein A in particles in exhaled air (PExA), bronchial lavage and bronchial wash - a methodological comparison
por: Behndig, Annelie F., et al.
Publicado: (2019)

Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes
por: Heinrich, B, et al.
Publicado: (2017)

Safety study supports clinical development of immunotherapeutic oncolytic measles vaccine
por: Engeland, Christine E.
Publicado: (2022)

Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity
por: Angelova, Assia L., et al.
Publicado: (2017)

The development of an effective synthetic route of lesinurad (RDEA594)
por: Meng, Qing, et al.
Publicado: (2017)

KG2Vec: A node2vec-based vectorization model for knowledge graph
por: Wang, YueQun, et al.
Publicado: (2021)

PTPD: predicting therapeutic peptides by deep learning and word2vec
por: Wu, Chuanyan, et al.
Publicado: (2019)

Multiagent Systems Based Modeling and Implementation of Dynamic Energy Management of Smart Microgrid Using MACSimJX
por: Raju, Leo, et al.
Publicado: (2016)

Relativistic treatment of spin-transfer observables in quasielastic ($\vec{\bf p},\vec{\bf n}$) scattering
por: Horowitz, C J, et al.
Publicado: (1994)

Specialists, Scientists, and Sentiments: Word2Vec and Doc2Vec in Analysis of Scientific and Medical Texts
por: Chen, Qufei, et al.
Publicado: (2021)

Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
por: Mostafa, Ahmed A., et al.
Publicado: (2018)

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning
por: Pol, Jonathan G, et al.
Publicado: (2020)

Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens
por: Luo, Yong, et al.
Publicado: (2020)

Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements
por: Yun, Chae-Ok, et al.
Publicado: (2022)

Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic
por: Zou, Hai, et al.
Publicado: (2022)

594 Life-Threatening Angioedema without Urticaria (Ae-U)
por: Corey, Jacquelynne, et al.
Publicado: (2012)

SUN-594 Pubertal Timing and Hormonal Correlates in Male Obesity
por: De Schepper, Jean, et al.
Publicado: (2020)

Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation
por: Simon, Sonja C. S., et al.
Publicado: (2023)

Speeding up software with VecCore
por: Amadio, G, et al.
Publicado: (2018)

VecGeom persistency using ROOT
por: Senacheribbe, Andrea
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8q3lltlujfi36tdebvld7jkj9n